Description: This article discusses the regulatory changes in Bermuda. There is an international initiative to review all insurance regulation by the International Association of Insurance Supervisors IAIS and the International Monetary Fund IMF.

Description: This article is the testimony of the author to the New York State Assembly Standing Committee on Insurance expressing his views about a proposed law to allow a domestic mutual life insurer to reorganize as a stock company that is owned by a mutual holding company.

Description: Author highlights historical nonforfeiture and federal tax law changes, as they have impacted life product designs, in prognosticating about future product designs.

Description: Actuarial Guideline 38 has been one of the most discussed reserving changes in the past year. First proposed in late summer of 2004, several industry groups and LHATF have worked to reach consensus on this issue. The current draft is a compromise, sometimes referred to as the “CEO compromise” since the CEOs of several leading life insurers negotiated the language. From Small Talk Newsletter, November 2005, Issue No. 25.

Description: The document is a Call for Proposals issued by the Society of Actuaries Research Institute's Research Executive Committee, outlining the background, purpose, research objectives, suggested topic areas, proposal requirements, evaluation criteria, selection process, submission guidelines, and conditions for funding high-quality research projects related to emerging issues in actuarial practice areas.

Description: As AI becomes more pervasive, we must consider the potential repercussions and risks associated with its widespread use. The SOA seeks essays that delve into the multifaceted risks posed by (AI) over both the short and long term.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This webcast will update listeners on the financial status of the U.S. Social Security program, describe half a dozen widespread myths, and discuss the reality of "waste, fraud and abuse" in the program.

Description: Medicare Advantage Organizations (MAOs) have made dramatic changes to the benefits and plan premiums they've offered members over the past years. Hear about information on the changes to benefits and plan premiums offered over the past few years. Find out where these strategic items are currently (for CY2024 bid year) and get ideas on what might come in the next few years. Presenters will discuss recent proposals and rules from CMS that will impact the current and future landscape. They will also compare these items in relation to the fee-for-service (FFS) Medicare market. This session will help you gain a deeper knowledge of the Medicare Advantage, Prescription Drug Plan, and Medicare FFS landscape and walk away with some strategic thoughts on potential paths MAOs may take from here.

Description: It's your first full day of productive learning! Start it off right with a delicious breakfast and warm welcome.